Identifying and Documenting Adverse Events at Clinical Study Sites

Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.

Related Content:

View from BrusselsApplied Clinical Trials-05-01-2002

Rhetoric and Realism Colliding on EU Discussions of Drug Repurposing

NICE Consults On Its New Assessment Scheme Amid A Blizzard Of Spin

HERA, A Matriach's Device to Save Europeans from the Next COVID